Drug class in one race
GPRC5D drugs for Multiple Myeloma
7 tracked GPRC5D drugs in the Multiple Myeloma race. The class explanation lives on the GPRC5D page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
1 Phase 33 Phase 1/22 Phase 11 preclinical / unstaged
Head-to-head evidence: Arlocabtagene autoleucel vs AZD0305 · Arlocabtagene autoleucel vs CAR-GPRC5D (RD118, IASO Biotherapeutics) · Arlocabtagene autoleucel vs CT071 · Arlocabtagene autoleucel vs JNJ-87562761 · Arlocabtagene autoleucel vs OriCAR-017 · Arlocabtagene autoleucel vs SAR446523